Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
Journal: Radiology
Published: March 31, 2026
Clinical Trial Protocol for LPS-Boost: Intensified [177Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 08, 2026
Prognostic Value of Cycle 1 SPECT SUVmean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 30, 2025
Results from a prospective registry of 18F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PET.
Journal: American journal of nuclear medicine and molecular imaging
Published: June 23, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.
Journal: European urology
Published: April 23, 2025
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study.
Journal: Urologic oncology
Published: March 24, 2025
Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency.
Journal: European urology oncology
Published: February 14, 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping.
Journal: Urologic oncology
Published: December 31, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 31, 2024
Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study.
Journal: Clinical genitourinary cancer
Published: May 21, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Journal: JCO precision oncology
Published: April 25, 2024
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 26, 2024
Last Updated: 09/26/2026